Demegenís natural and novel peptides are being developed for the treatment or prevention of bacterial and fungal infections, including multi-drug resistant varieties. Drug resistance has become a very serious health care issue. New solutions are needed.
Demegen's product development is accomplished through collaborations or licenses with corporate, university and government researchers. The D2A21 peptide is currently in a Phase 3 clinical trial for burn wounds. The P113 peptide has completed a Phase 2 clinical trial for oral candidiasis. Other potential applications include treatments for dermatological, vaginal, respiratory, and ophthalmic diseases.
Peptides are small proteins. More than 400 antimicrobial peptides have been discovered in nature. They function as part of the immune systems of animals, insects and plants. These new drugs may be a powerful new tool to combat bacterial, fungal and viral infections. Generally, the peptides bind to and kill harmful microorganisms.
Demegenís peptide portfolio includes a family of peptides derived from naturally occurring peptides found in human saliva, called "histatins" which play a role in the body's natural defense against disease. In addition, the portfolio includes two de novo synthetic classes that have demonstrated excellent activity against pathogens along with low toxicity.
Demegen's peptide technology may also be used genetically to prevent serious damage to crops caused by fungal and bacterial diseases. Academic and government researchers have reported successful results in many plant species.